Active ingredients: raloxifene
What it is used for
EVIFYNE is indicated for the prevention and treatment of osteoporosis in post-menopausal women. EVIFYNE is indicated for the reduction in the risk of invasive breast cancer in postmenopausal women with osteoporosis. EVIFYNE is indicated for the reduction in the risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer. High risk of breast cancer is defined as at least one breast biopsy showing lobular carcinoma in situ (LCIS) or atypical hyperplasia, one or more first-degree relatives with breast cancer, or a 5-year predicted risk of breast cancer >1.66% (based on the modified Gail model). Among the factors included in the modified Gail model are the following: current age, number of first-degree relatives with breast cancer, number of breast biopsies, age at menarche, nulliparity or age of first live birth. Currently, no single clinical finding or test result can quantify risk of breast cancer with certainty.
How to take it
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
- The way to take this medicine: Oral
- Store below 30 degrees Celsius
- Lifetime is 2 Years.
Always read the label. If symptoms persist see your healthcare professional.
White oval film coated tablet with 4165 printed in blue ink on one side
Images are the copyright of the Pharmacy Guild of Australia
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Pregnant or planning a pregnancy?
For the active ingredient raloxifene
This medicine is not considered safe during pregnancy. You should discuss this medicine with your doctor or pharmacist. They can help you balance the risks and the benefits of this medicine during pregnancy.
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf)